FDA unauthorizes use of Regeneron, Eli Lilly antibody treatments; new version of omicron reported Live COVID 19 updates

over 3 years in USA Today

The FDA said the two treatments are unlikely to work against the omicron variant, which makes up 99% of U.S. cases. Latest COVID-19 news.     

Mentioned in this news
Share it on